Evidence map›Paper›PMID 27310949›Full record

Trial reportMedicine2016

Lower serum uric acid level predicts mortality in dialysis patients.

Eunjin Bae, Hyun-Jeong Cho, Nara Shin, Sun Moon Kim, Seung Hee Yang, Dong Ki Kim, Yong-Lim Kim, Shin-Wook Kang, Chul Woo Yang, Nam Ho Kim and 2 more

Erratum issuedAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Lower time-averaged serum uric acid was associated with increased mortality in peritoneal dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Urate-lowering therapy for patients with gout on hemodialysis.International journal of rheumatic diseases · 2022
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Eunjin BaeDepartment of Internal Medicine, Gyeongsang National University Hospital, Changwon Department of Internal Medicine, Seoul National University Hospital Department of Internal Medicine, Yeolin Medical Foundation, Seoul Department of Internal Medicine, Chungbuk National University Hospital, Cheongju Kidney Research Institute, Seoul National University, Seoul Department of Internal Medicine, Kyungpook National University Hospital, Daegu Department of Internal Medicine, Yonsei University College of Medicine Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea.
Hyun-Jeong Cho
Nara Shin
Sun Moon Kim
Seung Hee Yang
Dong Ki Kim
Yong-Lim Kim
Shin-Wook Kang
Chul Woo Yang
Nam Ho Kim
Yon Su Kim
Hajeong Lee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the impact of serum uric acid (SUA) on mortality in patients with chronic dialysis. A total of 4132 adult patients on dialysis were enrolled prospectively between August 2008 and September 2014. Among them, we included 1738 patients who maintained dialysis for at least 3 months and had available SUA in the database. We categorized the time averaged-SUA (TA-SUA) into 5 groups: <5.5, 5.5-6.4, 6.5-7.4, 7.5-8.4, and ≥8.5 mg/dL. Cox regression analysis was used to calculate the hazard ratio (HR) of all-cause mortality according to SUA group. The mean TA-SUA level was slightly higher in men than in women. Patients with lower TA-SUA level tended to have lower body mass index (BMI), phosphorus, serum albumin level, higher proportion of diabetes mellitus (DM), and higher proportion of malnourishment on the subjective global assessment (SGA). During a median follow-up of 43.9 months, 206 patients died. Patients with the highest SUA had a similar risk to the middle 3 TA-SUA groups, but the lowest TA-SUA group had a significantly elevated HR for mortality. The lowest TA-SUA group was significantly associated with increased all-cause mortality (adjusted HR, 1.720; 95% confidence interval, 1.007-2.937; P = 0.047) even after adjusting for demographic, comorbid, nutritional covariables, and medication use that could affect SUA levels. This association was prominent in patients with well nourishment on the SGA, a preserved serum albumin level, a higher BMI, and concomitant DM although these parameters had no significant interaction in the TA-SUA-mortality relationship except DM. In conclusion, a lower TA-SUA level <5.5 mg/dL predicted all-cause mortality in patients with chronic dialysis.

Indexed as

AdultBiomarkersFemaleFollow-Up StudiesHumansKidney Failure, ChronicMaleMiddle AgedPrognosisProspective StudiesRenal DialysisRepublic of KoreaRisk FactorsSurvival RateTime FactorsUric AcidBiomarkersUric Acid

Identifiers

PMID27310949
PMCPMC4998435

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.